Please assess the completion status of the following clinical trial:

Trial Title: The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Persistence phase:~* A male or female who was between and including 10 and 25 years of age at the time of primary vaccination in the study with NCT number = 00454909.~* Written informed consent obtained from parents/guardian of the subject and written informed assent obtained from the subject if the subject is less than 18 years of age, or written informed consent obtained from the subject if the subject has achieved the 18th birthday.~* Healthy subjects as established by medical history.~* Having completed the active phase of the vaccination study with NCT number = 00454909.~Booster phase:~* Written informed consent obtained from parents/guardian of the subject and written informed assent obtained from the subject if the subject is less than 18 years of age, or written informed consent obtained from the subject if the subject has achieved the 18th birthday.~* Subjects who the investigator believes can and will comply with the requirements of the protocol should be enrolled in the study.~* Healthy subjects as established by medical history and history-directed physical examination before entering into the study.~* If the subject is female, she must be of non-childbearing potential, i.e., pre-menarche, have a current tubal ligation, hysterectomy, oophorectomy or be post-menopausal, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test on the day of vaccination and continue adequate contraception for 2 months after vaccination.~Additional inclusion criterion for the naïve control group:~• A male or female between, and including, 15 and 30 years of age at the time of the vaccination.~Exclusion Criteria:~Persistence phase:~* Use of any investigational or non-registered product within 30 days of each persistence time point.~* Vaccination with meningococcal polysaccharide or conjugate vaccine of serogroup A, C, W-135, and/or Y outside of study with NCT number = 00454909.~* History of any meningococcal disease due to serogroup A, B, C, W-135, or Y.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history.~* Administration of immunoglobulins and/or any blood products within the three months preceding each persistence time point.~* Concurrently participating in another clinical study within 30 days of each persistence time point, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy.~* Chronic alcohol or drug abuse.~* Subjects withdrew consent to be contacted for follow-up studies.~Booster phase (to be checked at Year 5 for all subject, including naïve control group):~* Child in care~* Not enrolled in the Kaiser Healthcare system.~* Use of any investigational or non-registered product within 30 days preceding administration of the study vaccine, or planned use throughout the extended safety follow-up period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior administration of the booster dose.~* Previous vaccination with meningococcal polysaccharide or conjugate vaccine of serogroup A, C, W-135, and/or Y outside of study with NCT number = 00454909.~* History of any meningococcal disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition,including human immunodeficiency virus infection based on medical history and physical examination.~* Administration of immunoglobulins and/or any blood products within the three months preceding the booster vaccination or planned administration through Day 30 after vaccination.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy.~* History of chronic alcohol consumption and/or drug abuse.~* Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting 30 days before until 30 days after the day of administration of the dose of vaccine(s) with the exception of any licensed inactivated influenza vaccine.~* Previous vaccination with tetanus and diphtheria toxoids within the last month.~* A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.~* History of allergic disease or any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine, including latex.~* Major congenital defects or serious chronic illness.~* History of any neurological disorders or seizures.~* Previous history of Guillain-Barré syndrome~* Acute disease at the time of vaccination.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions within 2 months after vaccination.~* For groups A, B and C only: Subjects withdrew consent to be contacted for follow-up studies.~Note: if the subject is female, prior to vaccination she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test on the day of vaccination and continue adequate contraception for 2 months after vaccination.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Nimenrix 1 Group (Type: EXPERIMENTAL): Subjects 11-25 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
- Menactra Group (Type: ACTIVE_COMPARATOR): Subjects 11-25 years of age who were previously vaccinated with 1 dose of Menactra vaccine at the time of vaccination
- Nimenrix 2 Group (Type: EXPERIMENTAL): Subjects 10\<11 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
- Nimenrix Naive Group (Type: EXPERIMENTAL): Subjects 15 to \<31 years of age at the time of primary vaccination with 1 dose of Nimenrix vaccine at year 5 of the current study
- Nimenrix Pooled Group (Type: EXPERIMENTAL): Pooled group of subjects 10-25 years of age from Nimenrix 1 and Nimenrix 2 groups in the primary study (NCT00454909) who had received 1 dose of Nimenrix vaccine in that study and will receive a booster dose in this current study.
- Menactra Booster Group (Type: ACTIVE_COMPARATOR): Subjects 11-25 years of age who had received 1 dose of Menactra vaccine in primary study (NCT00454909) and will receive 1 dose of Nimenrix vaccine in this current study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete